Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > GUD Announces Approval of Lenvima® in Columbia
View:
Comment by GoldenInvestor on Jan 04, 2022 9:08am
Exciting new addition. 5200+ and 2300  oatients for treatment options available for this treatment option! & this is in Colombia alone.  Lots more opportunities lots more opportunity for this drug in all other south americaan countries to come!!! GUD times!  GUD job team!
Comment by MrMugsy on Jan 04, 2022 9:19am
Just looked at the product roadmap GoldenInvestor ... Lenvima has already beein launched in "Argentina" and in "other" geographies.  If I'm reading it correctly - Brazil will be launched first and eventually it will be launched in Columbia. No other geographies planned for this drug.
Comment by GoldenInvestor on Jan 04, 2022 1:32pm
Even Better!   - thanks for the clarification. -now use can start to uptake , hopefully, with more and more patients starting to see their doctors, virtually or otherwise and prescriptions get rolling!
Comment by gudisgood on Jan 06, 2022 5:46am
MrMugsy, where did you see that info? The Product Pipeline PDF on the website shows that Lenvima has been: 1) "Marketed" in Brazil 2) "Launched" in Argentina and Others. An updated version would now show "Approved" for Colombia, of course. From the Investor Presentation file we can also see "Pending approval in Colombia, Uruguay, Bolivia and Paraguay" ...more  
Comment by MrMugsy on Jan 06, 2022 8:29am
Yes - Halvana approved today !
Comment by MrMugsy on Jan 06, 2022 8:46am
Yes - if I'm not mistaken, launch is the final stage, where Knight is selling the drug. To get there, you need to market it - as you can see EXELON is marketed but not launched yet. So the order is ... 1.Pre-registration, 2.Submit, 3.Approval, 4.Marketed, 5.Launched (as seen at the bottom of the pipeline page) With respect to Lenvima, the pipeline page shows it has been launched in Argentina ...more  
Comment by gudisgood on Jan 06, 2022 2:26pm
If believe it's Launched -> Marketed. If you go to the Annual Information Form (2020) page 30, you'll see the following definitions, which simply refer to the time the drug has been in a particular market: Launched: product has been on the market under 5 years Marketed: product has been on the market over 5 years So Exelon is "Marketed" because it's been "on the ...more  
Comment by kentucky77 on Jan 06, 2022 4:40pm
The pipline is starting to fill up with Marketed.... for more additions through M&A.   GLTA     ( The order is 1.Pre-registration, 2.Submit, 3.Approval, 4. Launched 5. Marketed )
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities